Study of Troxerutin to Prevent Blood Clots in Adults with Mild or Severe COVID-19

What this Trial Is About

Researchers are evaluating whether troxerutin can help prevent blood clots in adults with mild or severe COVID-19. This Phase 1 clinical trial aims to compare troxerutin with a placebo to see if it reduces thrombotic events and to assess the safety of troxerutin in this patient group. The study addresses key questions about how often blood clots occur and what side effects may happen during treatment. Participants will receive either oral troxerutin tablets or matching placebo tablets twice daily for 7 days. Some groups will also receive low molecular weight heparin once daily. The study includes four visits to the clinic on days 1, 4, 7, and 28 for checkups and tests. Participants will keep a diary tracking symptoms, blood clot events, bleeding events, and a specific blood platelet condition related to heparin. During the study, researchers will monitor participants health through clinical assessments and laboratory tests to measure the number of patients in a prothrombotic state over 7 days. Safety will be evaluated by recording any adverse events through 28 days. The total involvement includes treatment and follow-up visits over about four weeks, ensuring close observation of participants responses and any side effects.

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients